David Entenberg

Dr. David Entenberg

Department of Anatomy and Structural Biology, Einstein College of Medicine / Montefiore Medical Center, New York, United States
orcid

Research Focus & Metrics

Academic Career Length

23Years (2004-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 September 2015 in Cancer Discovery
Verified
Journal Article
Closed access
PDF file
AHAllison S. Harney
Allison S. Harney
EAEsther N. Arwert
Esther N. Arwert
DEDavid Entenberg
David Entenberg
YWYarong Wang
Yarong Wang
PGPeng Guo
Peng Guo
JCJohn S. Condeelis
John S. Condeelis
Dissemination of tumor cells is an essential step in metastasis. Direct contact between a macrophage, mammalian-enabled (MENA)–overexpressing tumor cell, and endothelial cell [Tumor MicroEnvironment of Metastasis (TMEM)] correlates with metastasis in breast cancer patients. Here we show, using intravital high-resolution two-photon microscopy, that transient vascular permeability and tumor cell intravasation occur simultaneously and exclusively at TMEM. The hyperpermeable nature of tumor vasculature is described as spatially and temporally heterogeneous. Using real-time imaging, we observed that vascular permeability is transient, restricted to the TMEM, and required for tumor cell dissemination. VEGFA signaling from TIE2hi TMEM macrophages causes local loss of vascular junctions, transient vascular permeability, and tumor cell intravasation, demonstrating a role for the TMEM within the primary mammary tumor. These data provide insight into the mechanism of tumor cell intravasation and vascular permeability in breast cancer, explaining the value of TMEM density as a predictor of distant metastatic recurrence in patients. Significance: Tumor vasculature is abnormal with increased permeability. Here, we show that VEGFA signaling from TIE2hi TMEM macrophages results in local, transient vascular permeability and tumor cell intravasation. These data provide evidence for the mechanism underlying the association of TMEM with distant metastatic recurrence, offering a rationale for therapies targeting TMEM. Cancer Discov; 5(9); 932–43. ©2015 AACR. See related commentary by Kadioglu and De Palma, p. 906. This article is highlighted in the In This Issue feature, p. 893

14 December 2016 in Nature
Verified
Journal Article
Closed access
PDF file
KHKathryn L. Harper
Kathryn L. Harper
MSMaria Soledad Sosa
Maria Soledad Sosa
DEDavid Entenberg
David Entenberg
HHHedayatollah Hosseini
Hedayatollah Hosseini
JCJulie F. Cheung
Julie F. Cheung
JAJulio A. Aguirre-Ghiso
Julio A. Aguirre-Ghiso

5 July 2017 in Science Translational Medicine
Verified
Journal Article
Closed access
PDF file
GKGeorgios S Karagiannis
Georgios S Karagiannis
JPJessica M. Pastoriza
Jessica M. Pastoriza
YWYarong Wang
Yarong Wang
AHAllison S. Harney
Allison S. Harney
DEDavid Entenberg
David Entenberg
MOMaya H Oktay
Maya H Oktay
Breast cancer cells disseminate through TIE2/MENACalc/MENAINV-dependent cancer cell intravasation sites, called tumor microenvironment of metastasis (TMEM), which are clinically validated as prognostic markers of metastasis in breast cancer patients. Using fixed tissue and intravital imaging of a PyMT murine model and patient-derived xenografts, we show that chemotherapy increases the density and activity of TMEM sites and Mena expression and promotes distant metastasis. Moreover, in the residual breast cancers of patients treated with neoadjuvant paclitaxel after doxorubicin plus cyclophosphamide, TMEM score and its mechanistically connected MENAINV isoform expression pattern were both increased, suggesting that chemotherapy, despite decreasing tumor size, increases the risk of metastatic dissemination. Chemotherapy-induced TMEM activity and cancer cell dissemination were reversed by either administration of the TIE2 inhibitor rebastinib or knockdown of the MENA gene. Our results indicate that TMEM score increases and MENA isoform expression pattern changes with chemotherapy and can be used in predicting prometastatic changes in response to chemotherapy. Furthermore, inhibitors of TMEM function may improve clinical benefits of chemotherapy in the neoadjuvant setting or in metastatic disease.

14 February 2004 in Analytical Chemistry
Verified
Journal Article
Closed access
JVJosep Villanueva
Josep Villanueva
JPJohn Philip
John Philip
DEDavid Entenberg
David Entenberg
CCCarlos A. Chaparro
Carlos A. Chaparro
MTMeena K. Tanwar
Meena K. Tanwar
Paul TempstPaul Tempst
Paul Tempst

1 January 2019 in Cancer Discovery
Verified
Journal Article
Closed access
PDF file
XLXia Liu
Xia Liu
RTRokana Taftaf
Rokana Taftaf
MKMadoka Kawaguchi
Madoka Kawaguchi
YCYa-Fang Chang
Ya-Fang Chang
WCWenjing Chen
Wenjing Chen
HLHuiping Liu
Huiping Liu
Circulating tumor cells (CTC) seed cancer metastases; however, the underlying cellular and molecular mechanisms remain unclear. CTC clusters were less frequently detected but more metastatic than single CTCs of patients with triple-negative breast cancer and representative patient-derived xenograft models. Using intravital multiphoton microscopic imaging, we found that clustered tumor cells in migration and circulation resulted from aggregation of individual tumor cells rather than collective migration and cohesive shedding. Aggregated tumor cells exhibited enriched expression of the breast cancer stem cell marker CD44 and promoted tumorigenesis and polyclonal metastasis. Depletion of CD44 effectively prevented tumor cell aggregation and decreased PAK2 levels. The intercellular CD44–CD44 homophilic interactions directed multicellular aggregation, requiring its N-terminal domain, and initiated CD44–PAK2 interactions for further activation of FAK signaling. Our studies highlight that CD44+ CTC clusters, whose presence is correlated with a poor prognosis of patients with breast cancer, can serve as novel therapeutic targets of polyclonal metastasis. Significance: CTCs not only serve as important biomarkers for liquid biopsies, but also mediate devastating metastases. CD44 homophilic interactions and subsequent CD44–PAK2 interactions mediate tumor cluster aggregation. This will lead to innovative biomarker applications to predict prognosis, facilitate development of new targeting strategies to block polyclonal metastasis, and improve clinical outcomes. See related commentary by Rodrigues and Vanharanta, p. 22. This article is highlighted in the In This Issue feature, p. 1

23 January 2017 in Nature Cell Biology
Verified
Journal Article
Closed access
PDF file
GFGeorg Flügen
Georg Flügen
AAAlvaro Avivar-Valderas
Alvaro Avivar-Valderas
YWYarong Wang
Yarong Wang
MPMichael R. Padgen
Michael R. Padgen
JWJames K. Williams
James K. Williams
JAJulio A. Aguirre-Ghiso
Julio A. Aguirre-Ghiso